Business context and reporting period
iSpecimen Inc. (Nasdaq: ISPC) filed this Form 8-K on October 30, 2026, reporting the result of Proposal No. 2 at the reconvened portion of its special stockholders’ meeting. The meeting had been adjourned on October 9 for this proposal; results for the other proposals were reported separately.
Key filing facts
- Stockholders approved an amendment authorizing a reverse stock split of the company’s common stock at a ratio from 1-for-10 to 1-for-100, with the exact ratio left to the Board’s discretion.
- Votes: 1,152,016 for; 142,944 against; 868 abstentions; no broker non-votes. Under the stated voting standard, votes for had to exceed votes against; abstentions did not affect the outcome.
- Of 2,518,590 shares outstanding and entitled to vote as of the August 12, 2026 record date, 1,295,828 were present or represented by proxy, constituting approximately 51.5% and establishing a quorum.
Financial performance and outlook
This filing reports no revenue, profit, cash flow, margin, debt, liquidity, or other operating results. It provides no financial guidance or outlook.
Material changes, commentary, and risks
The material event is stockholder approval of the reverse-split authorization. The filing does not state that the split has been effected, identify the selected ratio, or provide an effective date. No additional management commentary, contingencies, or unusual financial items are disclosed.
Investor verification points
- Check subsequent company filings for whether the Board implements the split and what ratio and effective date it selects.
- Review the proxy statement and its October 19, 2026 supplement for the proposal’s detailed terms and rationale.
- Confirm any later disclosures about changes to the share count or trading arrangements following implementation.